Hepatitis C

The World Health Organization has set a goal of eradication for HCV by 2030.

The prevalence of HBV among people who inject drugs was highest in East and Southeast Asia and lowest in Western Europe.

The average hepatitis C virus incidence was 52% lower during the broad-DAA access period.

The results show significant LSM relative reductions compared to pooled placebo in aspartate aminotransferase for pegozafermin 3 mg once weekly, 27 mg once weekly, and 36 mg once every 2 weeks.

The treatment rate decreased from 64.8% to 61.2% after 2018.

Sustained virologic response was reached by 98% of the study at 12 weeks following the conclusion of treatment and remained consistent among genotype, HCV RNA values, fibrosis stage, and the subgroup of interest.

They also found a high-risk perception of HBV was associated with the willingness to be vaccinated against hepatitis B in participants from either province.

RBX2660 is the first live microbiota therapeutic approved by the FDA.

The pooled proportions of virological relapse and clinical relapse after discontinuing treatment in cirrhotic patients was 55.23 and 43.56%, respectively.

The incidence of NAFLD was 263.9 cases per 100,000 person-years in the infectious mononucleosis group, compared to 164.5 cases per 100,000 person-years in individuals without it.

HBsAg-positive women with adequate gestational weight again among pre-pregnancy normal-weight women had a higher risk of gestational diabetes mellitus than HBs-Ag-negative women.

For NASH or NAFLD publications, the number of publications were on a continuous upward slope throughout the study period and finally surpassed HCV studies in 2020.

There was a similar prevalence of NAFLD in patients who were overweight as there was for individuals who were obese.

The mean daily adherence was higher in the mDOT group compared to the patient navigation group.

Overall, 82 participants agreed to receive DBS testing, 28% of which reported that the aspects of the program made them feel uncomfortable.

The efficacy of H pylori treatments has waned in recent years, largely because of clarithromycin resistance.

The FDA recently approved a drug treatment for HBV infection for pediatric patients 12 and older with compensated liver disease.

Patients with NAFLD were more likely to have comorbidities, including diabetes, hypertension, chronic respiratory disease, hypothyroidism, chronic kidney disease, sleep apnea, and hyperlipidemia.

Approximately 5% of nurses in Mozambique were infected with hepatitis B virus during a 3-month period in 2020.

"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.

The estimated annual percentage change was signficiantly associated with a baseline age-standardized incidence rate of less than 5500 per 100,000 individuals.

Treatment initiation was lower among Medicaid and private health insurance recipients aged 18-29 years, compared with patients aged 50-59 years.

In Philadelphia, 28% of the patient population was unscreened, with the factors associated with lower risks of being unscreened generally associated with a higher HCV positivity rate.

The approval, awarded to Alnylam Pharmaceuticals, is based on the results of the ILLUMINATE-C phase 3 trial.

The risk of cirrhosis increased supramultiplicatively in patients with obesity, with excessive drinking, and who were homozygous carriers.

The investigators found minor differences in the microbial community structure between the control group and the chronic HCV group.

NAFLD resulted in a number of other negative outcomes, including sleep disturbance, cardiovascular disease, significant hepatic fibrosis, and advanced hepatic fibrosis.

The association between cumulative BMI and risk of NAFLD was more pronounced in women and younger participants.

A significantly lower rate of C difficile resolution was found in the placebo group compared to the FMT group.